Updated: Feb 7, 2021
Lupin Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 160 drugs in the United States.
Lupin is interested in entering the digital health / digital therapeutic sector
DTxCC conducts a commercial assessment to develop a clear understanding of the US marketplace and opportunities for a digital health/therapeutic offering
ROI/NPV Investment Evaluation
Incremental sales forecast
Supporting evidence/promotions needed for commercial success
Organizational capabilities needed for commercial success